Amphotericin B-induced nephrotoxicity: A review

Journal of Chemotherapy

Volumn 12, Issue 6, 2000, Pages 463-470

  Fanos, V ^a   Cataldi, L ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Amphotericin B; Fungal infections; Mycoses; Nephrotoxicity; Toxicity

Indexed keywords

AMPHOTERICIN B; DOPAMINE; FUROSEMIDE;

ACUTE KIDNEY FAILURE; AGE DISTRIBUTION; ARTERY CONSTRICTION; CLINICAL FEATURE; HUMAN; KIDNEY ARTERY; KIDNEY TUBULE DAMAGE; LABORATORY TEST; MYCOSIS; NEPHROTOXICITY; PATHOPHYSIOLOGY; PATIENT MONITORING; REVIEW;

EID: 0034525028     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2000.12.6.463     Document Type: Review

References (53)

1. Amphotericin toxicity
2. Amphotericin B therapy: Past, present, and future
3. Candida infections in neonates: A review
4. Nephrotoxicity of antiinfective drugs
5. On the development of antifungal agents: Perspective of the U.S. Food and Drug Administration
6. Laboratory evaluation of antifungal agents: A brief overview
7. Therapy for opportunistic fungal infections: Past, present and future
8. In vitro and in vivo evaluation of antifungal agents
9. Liposomal and lipid-based formulations of amphotericin B
10. Lipid formulations of amphotericin B: Recent progress and future direction
11. Drug-induced nephrotoxicity. Aetiology, clinical features and management
12. Antibiotic-related nephrotoxicity
13. Distribution and activity of amphotericin B in humans
14. Pharmacokinetic outcome and toxic effects of amphotericin B and 5 fluorocytosine in neonates
15. Direct amphotericin B-mediated tubular toxicity: Assessment of selected cytoprotective agents
16. Amphotericin B nephrotoxicity: The adverse consequence of altered membrane properties
17. Amphotericin B: Current understanding of mechanism of action
18. Amphotericin B toxicity
19. Mechanism of amphotericin B-induced reduction of glomerular filtration rate
20. Basic mechanism of aminoglycoside nephrotoxicity
21. Amphotericin B as a single agent in the treatment of systemic candidiasis in neonates
22. Risk factor for amphotericin B-associated nephrotoxicity
23. Lipid formulations of amphotericin B: Clinical efficacy and toxicities
24. Lipid-based amphotericin B for the treatment of fungal infections
25. AmBisome: An overview of current use
26. Cost-effectiveness analysis of treatment with liposomal amphotericin B versus conventional amphotericin B in organ or bone marrow transplant recipients with systemic mycoses
27. Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients
28. Safety and efficacy of amphotericin B colloidal dispersion. An overview
29. Renal sparing by amphotericin B colloidal dispersion: Clinical experience in 572 patients
30. Retrospective analysis of the dosage of amphotericin B lipid complex for the treatment of invasive fungal infections
31. Amphotericin B in children
32. Systemic candida infection in infants in intensive care nurseries: High incidence of central nervous system involvment
33. Lipid formulations of amphotericin B: Clinical perspectives for the management of invasive fungal infections in children with cancer
34. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknow origin in neutropenic patients
35. Amphotericin B in children with malignant disease: A comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion
36. Systemic fungal infections in neonates
37. Liposomal amphotericin B in neonates with invasive candidiasis
38. Liposomal amphotericin B treatment for neonatal fungal infections
39. Candida infection in very low birth-weight infants: Outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome)
40. Renal tolerance with the use of intralipid-amphotericin B in low-birth-weight neonates
41. Systemic anti-fungal agents. Drug interactions of clinical significance
42. Antibacterial induced nephrotoxicity in the newborn
43. Antibiotic treatment of infections in neonates: A review
44. Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow trasplantation
45. Antimicrobial survey on urinary tract isolated micro-organisms in a pediatric department
46. Antibiotic prophylaxis in children with relapsing urinary tract infections
47. Therapy of infections in patients with acute leukemia
48. Evolution of antifungal agents: Past, present, and future
49. Efficacy of low-dose dopamine in preventing amphotericin B nephrotoxicity in bone marrow transplant patients and leukemia patients
50. Amphotericin B-phospholipid interactions responsible for reduced mammalian toxicity
51. C-reactive protein and serum amyloid A in neonatal infections
52. Mechanisms and management of amphotericin B-induced nephrotoxicity